<?xml version='1.0' encoding='utf-8'?>
<document id="23913028"><sentence text="Ritonavir and efavirenz significantly alter the metabolism of erlotinib--an observation in primary cultures of human hepatocytes that is relevant to HIV patients with cancer."><entity charOffset="0-9" id="DDI-PubMed.23913028.s1.e0" text="Ritonavir" /><entity charOffset="14-23" id="DDI-PubMed.23913028.s1.e1" text="efavirenz" /><pair ddi="false" e1="DDI-PubMed.23913028.s1.e0" e2="DDI-PubMed.23913028.s1.e0" /><pair ddi="false" e1="DDI-PubMed.23913028.s1.e0" e2="DDI-PubMed.23913028.s1.e1" /></sentence><sentence text="Erlotinib is approved for the treatment of non-small cell lung and pancreatic cancers, and is metabolized by CYP3A4"><entity charOffset="0-9" id="DDI-PubMed.23913028.s2.e0" text="Erlotinib" /></sentence><sentence text=" Inducers and inhibitors of CYP3A enzymes such as ritonavir and efavirenz, respectively, may be used as part of the highly active antiretroviral therapy drugs to treat patients with human immunodeficiency virus (HIV)"><entity charOffset="50-59" id="DDI-PubMed.23913028.s3.e0" text="ritonavir" /><entity charOffset="64-73" id="DDI-PubMed.23913028.s3.e1" text="efavirenz" /><pair ddi="false" e1="DDI-PubMed.23913028.s3.e0" e2="DDI-PubMed.23913028.s3.e0" /><pair ddi="false" e1="DDI-PubMed.23913028.s3.e0" e2="DDI-PubMed.23913028.s3.e1" /></sentence><sentence text=" When HIV patients with a malignancy need treatment with erlotinib, there is a potential of as-yet-undefined drug-drug interaction"><entity charOffset="57-66" id="DDI-PubMed.23913028.s4.e0" text="erlotinib" /></sentence><sentence text=" We evaluated these interactions using human hepatocytes benchmarked against the interaction of erlotinib with ketoconazole and rifampin, the archetype cytochrome P450 inhibitor and inducer, respectively"><entity charOffset="96-105" id="DDI-PubMed.23913028.s5.e0" text="erlotinib" /><entity charOffset="111-123" id="DDI-PubMed.23913028.s5.e1" text="ketoconazole" /><entity charOffset="128-136" id="DDI-PubMed.23913028.s5.e2" text="rifampin" /><pair ddi="false" e1="DDI-PubMed.23913028.s5.e0" e2="DDI-PubMed.23913028.s5.e0" /><pair ddi="false" e1="DDI-PubMed.23913028.s5.e0" e2="DDI-PubMed.23913028.s5.e1" /><pair ddi="false" e1="DDI-PubMed.23913028.s5.e0" e2="DDI-PubMed.23913028.s5.e2" /><pair ddi="false" e1="DDI-PubMed.23913028.s5.e1" e2="DDI-PubMed.23913028.s5.e1" /><pair ddi="false" e1="DDI-PubMed.23913028.s5.e1" e2="DDI-PubMed.23913028.s5.e2" /></sentence><sentence text=" Hepatocytes were treated with vehicle [0" /><sentence text="1% dimethylsulfoxide, ritonavir (10 μM)], ketoconazole (10 μM), efavirenz (10 μM), or rifampin (10 μM) for 4 days"><entity charOffset="3-20" id="DDI-PubMed.23913028.s7.e0" text="dimethylsulfoxide" /><entity charOffset="22-31" id="DDI-PubMed.23913028.s7.e1" text="ritonavir" /><entity charOffset="42-54" id="DDI-PubMed.23913028.s7.e2" text="ketoconazole" /><entity charOffset="64-73" id="DDI-PubMed.23913028.s7.e3" text="efavirenz" /><entity charOffset="86-94" id="DDI-PubMed.23913028.s7.e4" text="rifampin" /><pair ddi="false" e1="DDI-PubMed.23913028.s7.e0" e2="DDI-PubMed.23913028.s7.e0" /><pair ddi="false" e1="DDI-PubMed.23913028.s7.e0" e2="DDI-PubMed.23913028.s7.e1" /><pair ddi="false" e1="DDI-PubMed.23913028.s7.e0" e2="DDI-PubMed.23913028.s7.e2" /><pair ddi="false" e1="DDI-PubMed.23913028.s7.e0" e2="DDI-PubMed.23913028.s7.e3" /><pair ddi="false" e1="DDI-PubMed.23913028.s7.e0" e2="DDI-PubMed.23913028.s7.e4" /><pair ddi="false" e1="DDI-PubMed.23913028.s7.e1" e2="DDI-PubMed.23913028.s7.e1" /><pair ddi="false" e1="DDI-PubMed.23913028.s7.e1" e2="DDI-PubMed.23913028.s7.e2" /><pair ddi="false" e1="DDI-PubMed.23913028.s7.e1" e2="DDI-PubMed.23913028.s7.e3" /><pair ddi="false" e1="DDI-PubMed.23913028.s7.e1" e2="DDI-PubMed.23913028.s7.e4" /><pair ddi="false" e1="DDI-PubMed.23913028.s7.e2" e2="DDI-PubMed.23913028.s7.e2" /><pair ddi="false" e1="DDI-PubMed.23913028.s7.e2" e2="DDI-PubMed.23913028.s7.e3" /><pair ddi="false" e1="DDI-PubMed.23913028.s7.e2" e2="DDI-PubMed.23913028.s7.e4" /><pair ddi="false" e1="DDI-PubMed.23913028.s7.e3" e2="DDI-PubMed.23913028.s7.e3" /><pair ddi="false" e1="DDI-PubMed.23913028.s7.e3" e2="DDI-PubMed.23913028.s7.e4" /></sentence><sentence text=" On day 5, erlotinib (5 μM) was incubated with the above agents for another 24-48 hours"><entity charOffset="11-20" id="DDI-PubMed.23913028.s8.e0" text="erlotinib" /></sentence><sentence text=" Concentrations of erlotinib and O-desmethyl erlotinib were quantitated in collected samples (combined lysate and medium) using liquid chromatography and tandem mass spectrometry"><entity charOffset="19-28" id="DDI-PubMed.23913028.s9.e0" text="erlotinib" /><entity charOffset="33-54" id="DDI-PubMed.23913028.s9.e1" text="O-desmethyl erlotinib" /><pair ddi="false" e1="DDI-PubMed.23913028.s9.e0" e2="DDI-PubMed.23913028.s9.e0" /><pair ddi="false" e1="DDI-PubMed.23913028.s9.e0" e2="DDI-PubMed.23913028.s9.e1" /></sentence><sentence text=" The half-life (t(½)) of erlotinib increased from 10"><entity charOffset="25-34" id="DDI-PubMed.23913028.s10.e0" text="erlotinib" /></sentence><sentence text="6 ± 2" /><sentence text="6 to 153 ± 80 and 23" /><sentence text="9 ± 4" /><sentence text="8 hours, respectively, upon treatment with ritonavir and ketoconazole"><entity charOffset="43-52" id="DDI-PubMed.23913028.s14.e0" text="ritonavir" /><entity charOffset="57-69" id="DDI-PubMed.23913028.s14.e1" text="ketoconazole" /><pair ddi="false" e1="DDI-PubMed.23913028.s14.e0" e2="DDI-PubMed.23913028.s14.e0" /><pair ddi="false" e1="DDI-PubMed.23913028.s14.e0" e2="DDI-PubMed.23913028.s14.e1" /></sentence><sentence text=" The apparent intrinsic clearance (C(Lint, app)) of erlotinib was lowered 16-fold by ritonavir and 1"><entity charOffset="52-61" id="DDI-PubMed.23913028.s15.e0" text="erlotinib" /><entity charOffset="85-94" id="DDI-PubMed.23913028.s15.e1" text="ritonavir" /><pair ddi="false" e1="DDI-PubMed.23913028.s15.e0" e2="DDI-PubMed.23913028.s15.e0" /><pair ddi="false" e1="DDI-PubMed.23913028.s15.e0" e2="DDI-PubMed.23913028.s15.e1" /></sentence><sentence text="9-fold by ketoconazole"><entity charOffset="10-22" id="DDI-PubMed.23913028.s16.e0" text="ketoconazole" /></sentence><sentence text=" Efavirenz and rifampin decreased t1/2 of erlotinib from 10"><entity charOffset="1-10" id="DDI-PubMed.23913028.s17.e0" text="Efavirenz" /><entity charOffset="15-23" id="DDI-PubMed.23913028.s17.e1" text="rifampin" /><entity charOffset="42-51" id="DDI-PubMed.23913028.s17.e2" text="erlotinib" /><pair ddi="false" e1="DDI-PubMed.23913028.s17.e0" e2="DDI-PubMed.23913028.s17.e0" /><pair ddi="false" e1="DDI-PubMed.23913028.s17.e0" e2="DDI-PubMed.23913028.s17.e1" /><pair ddi="false" e1="DDI-PubMed.23913028.s17.e0" e2="DDI-PubMed.23913028.s17.e2" /><pair ddi="false" e1="DDI-PubMed.23913028.s17.e1" e2="DDI-PubMed.23913028.s17.e1" /><pair ddi="false" e1="DDI-PubMed.23913028.s17.e1" e2="DDI-PubMed.23913028.s17.e2" /></sentence><sentence text="3 ± 1" /><sentence text="1 to 5" /><sentence text="0 ± 1" /><sentence text="5 and 3" /><sentence text="4 ± 0" /><sentence text="2 hours, respectively" /><sentence text=" Efavirenz and rifampin increased the C(Lint, app) of erlotinib by 2"><entity charOffset="1-10" id="DDI-PubMed.23913028.s24.e0" text="Efavirenz" /><entity charOffset="15-23" id="DDI-PubMed.23913028.s24.e1" text="rifampin" /><entity charOffset="54-63" id="DDI-PubMed.23913028.s24.e2" text="erlotinib" /><pair ddi="false" e1="DDI-PubMed.23913028.s24.e0" e2="DDI-PubMed.23913028.s24.e0" /><pair ddi="false" e1="DDI-PubMed.23913028.s24.e0" e2="DDI-PubMed.23913028.s24.e1" /><pair ddi="false" e1="DDI-PubMed.23913028.s24.e0" e2="DDI-PubMed.23913028.s24.e2" /><pair ddi="false" e1="DDI-PubMed.23913028.s24.e1" e2="DDI-PubMed.23913028.s24.e1" /><pair ddi="false" e1="DDI-PubMed.23913028.s24.e1" e2="DDI-PubMed.23913028.s24.e2" /></sentence><sentence text="2- and 2-fold, respectively" /><sentence text=" Our results suggest that to achieve desired drug exposure, the clinically used dose (150 mg daily) of erlotinib may have to be significantly reduced (25 mg every other day) or increased (300 mg daily), respectively, when ritonavir or efavirenz is coadministered"><entity charOffset="103-112" id="DDI-PubMed.23913028.s26.e0" text="erlotinib" /><entity charOffset="222-231" id="DDI-PubMed.23913028.s26.e1" text="ritonavir" /><entity charOffset="235-244" id="DDI-PubMed.23913028.s26.e2" text="efavirenz" /><pair ddi="false" e1="DDI-PubMed.23913028.s26.e0" e2="DDI-PubMed.23913028.s26.e0" /><pair ddi="false" e1="DDI-PubMed.23913028.s26.e0" e2="DDI-PubMed.23913028.s26.e1" /><pair ddi="false" e1="DDI-PubMed.23913028.s26.e0" e2="DDI-PubMed.23913028.s26.e2" /><pair ddi="false" e1="DDI-PubMed.23913028.s26.e1" e2="DDI-PubMed.23913028.s26.e1" /><pair ddi="false" e1="DDI-PubMed.23913028.s26.e1" e2="DDI-PubMed.23913028.s26.e2" /></sentence><sentence text="" /></document>